ReviewBreast care (Basel, Switzerland)2021

Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer.

Marija Balic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.